Elysium Basis is an oral supplement combining nicotinamide riboside and pterostilbene. It is not an NAD+ injection, an infusion service, or a prescription clinic. Its relevance to this publication comes from the company’s NAD-related research and marketing, which make a useful case study in reading evidence precisely.
We examined the official product and science pages alongside the published trial on September 23, 2026. This review does not report personal use, independently test capsules, or treat a change in a laboratory marker as proof that a supplement extends human life.
THE USEFUL DISTINCTION
The published study supports a specific NAD+ biomarker finding under its conditions, not a universal longevity promise.
What is being sold
Basis combines two ingredients rather than supplying the same intervention as injectable NAD+. NR is a precursor involved in NAD metabolism; pterostilbene is an additional compound in the studied combination. Evidence about either ingredient alone is not automatically a full evaluation of the combination.
Likewise, results for this combination should not be transferred to every product sold under an NAD support label. Our NAD, NR, and NMN comparison helps keep those names attached to the interventions they describe. Product category is the first distinction to preserve before comparing prices or advertised benefits.
Evidence: Elysium: Basis product and subscription terms / Dellinger et al.: 2017 NRPT randomized trial / Martens et al.: 2018 oral NR crossover trial
The trial behind the familiar headline
The 2017 randomized, double-blind, placebo-controlled trial enrolled 120 healthy adults aged 60 to 80 and lasted eight weeks. It investigated safety and tolerability, along with whole-blood NAD+ and additional measures. The reported NAD+ increase is a biomarker result in that study population and protocol.
The research was funded by Elysium, and the paper discloses relevant relationships. That does not automatically invalidate a result, but it is context a reader should be able to see. The study’s duration and size also limit conclusions about uncommon harms and effects over years.
What the result does not answer
An increase in whole-blood NAD+ does not by itself establish that people think more clearly, avoid disease, or live longer. Those questions require their own measured outcomes and adequately designed studies. A mechanism connecting NAD biology with aging is not a substitute for those clinical observations.
The NAD introduction explains this difference between biological plausibility, a marker, and a meaningful benefit. In our evidence explorer, the Basis trial sits beside two different interventions so readers can see why collecting all their results into one broad promise would be misleading.
Evidence: Dellinger et al.: 2017 NRPT randomized trial / Martens et al.: 2018 oral NR crossover trial / Grant et al.: 2019 IV NAD+ metabolome pilot
Read additional research on its own terms
Elysium’s science pages describe a broader research program and make claims about the product. A company summary is a useful route to the papers, but the original publication is where the population, endpoints, statistical limits, and conflicts should be checked. A study in a specific condition may not answer a healthy-aging question for the general population.
For example, clinical-function research involving oral NR in peripheral artery disease has a different study question from the original Basis biomarker trial. Neither should be used as blanket evidence that a compounded injectable preparation has the same effect.
Evidence: Elysium: Basis research explanation / McDermott et al.: 2024 NICE trial / Dellinger et al.: 2017 NRPT randomized trial
Subscription terms deserve a separate reading
The product page distinguishes monthly subscriptions from prepaid plans. Its published terms describe prepaid purchases as final sale, with cancellation taking effect after the remaining term, while monthly plans can be canceled before the next shipment. Confirm the exact terms and price presented to you before purchasing.
We do not give a universal current price here because package, promotion, and commitment can affect the offer. The cost guide explains why a supplement subscription and a prescription program should not be compared as if they purchase identical care. A discount is a financial term, not clinical evidence.
Where a supplement review stops
Discuss supplement use with a clinician or pharmacist who can consider your medical history, medicines, and goals. A product described as intended for healthy adults is not automatically appropriate for every adult. This review cannot resolve interactions, individual suitability, or a reason to replace established medical care.
Our CoreAge review and AgelessRx review concern a different category of compounded prescription products. The provider shortlist marks that difference and discloses CoreAge’s paid first position. No comparison here establishes an independently tested winner for clinical effectiveness.
Evidence: Elysium: Basis product and subscription terms / CoreAge Rx: NAD+ injectable product page / AgelessRx: NAD+ injections / FDA: compounding and approval
Open the source material
- Elysium: Basis product and subscription terms
Oral NR plus pterostilbene supplement, not injectable NAD+. Marketing and purchase terms are separate from clinical trial results.
- Dellinger et al.: 2017 NRPT randomized trial
120 adults aged 60–80, eight weeks; NAD+ biomarker and safety outcomes. Elysium funded the study; not evidence of longer life.
- Martens et al.: 2018 oral NR crossover trial
Small, short-duration human study of oral NR; cannot establish effectiveness of injectable NAD+.
- Grant et al.: 2019 IV NAD+ metabolome pilot
Eight NAD+ recipients and three saline controls; short-term metabolite measurements, not a longevity or clinical efficacy trial.
- Elysium: Basis research explanation
Sponsor description of research; read alongside the published paper and conflicts of interest.
- McDermott et al.: 2024 NICE trial
Randomized trial in peripheral artery disease. A condition-specific oral NR result is not general proof for all NAD products.
- CoreAge Rx: NAD+ injectable product page
Commercial description and starting price checked September 23, 2026. Benefit claims are not independent efficacy evidence.
- AgelessRx: NAD+ injections
Advertised $79 first month on a three-month plan billed in full, then $149 per month. Confirm final terms; surveys are not controlled trials.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
